1,150 results on '"Jauch, Anna"'
Search Results
2. Artificial intelligence–based, volumetric assessment of the bone marrow metabolic activity in [18F]FDG PET/CT predicts survival in multiple myeloma
3. Developmental signals control chromosome segregation fidelity during pluripotency and neurogenesis by modulating replicative stress
4. Application of an artificial intelligence-based tool in [18F]FDG PET/CT for the assessment of bone marrow involvement in multiple myeloma
5. Quantitative Integrative Survival Prediction in Multiple Myeloma Patients Treated With Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell Transplantation
6. A comparison of deep sclerectomy outcomes in eyes with pseudoexfoliation versus primary open angle glaucoma
7. Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma
8. Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial
9. Clonally resolved single-cell multi-omics identifies routes of cellular differentiation in acute myeloid leukemia
10. Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma—Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income Countries
11. Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial
12. Angiogenic and molecular diversity determine hepatic melanoma metastasis and response to anti-angiogenic treatment
13. Lyve-1 deficiency enhances the hepatic immune microenvironment entailing altered susceptibility to melanoma liver metastasis
14. STIL overexpression shortens lifespan and reduces tumor formation in mice.
15. Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients
16. Author Reply to Peer Reviews of STIL overexpression shortens lifespan and reduces tumor formation in mice
17. Functional interplay of Epstein-Barr virus oncoproteins in a mouse model of B cell lymphomagenesis
18. Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial
19. Selective elimination of immunosuppressive T cells in patients with multiple myeloma
20. Developmental signals control chromosome segregation fidelity during pluripotency and neurogenesis by modulating replicative stress
21. Artificial intelligence–based, volumetric assessment of the bone marrow metabolic activity in [18F]FDG PET/CT predicts survival in multiple myeloma.
22. Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial
23. Chromosome 8p engineering reveals increased metastatic potential targetable by patient-specific synthetic lethality in liver cancer
24. Compilation of Genotype and Phenotype Data in GCDH-LOVD for Variant Classification and Further Application
25. STIL overexpression shortens lifespan and reduces tumor formation in mice
26. The prognostic significance of [18F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs)
27. Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma
28. CD8+CD28−regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study
29. Neuroinfectiology of an atypical anthrax-causing pathogen in wild chimpanzees
30. RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma
31. Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma
32. Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial
33. OA-37 Optimization of the 20/2/20 risk stratification model for patients with smoldering multiple myeloma through integration of the evolving patterns of monoclonal protein and serum free light chains
34. OA-43 Analysis of sustained MRD-negativity and progression-free survival of Isa-KRd in high-risk newly diagnosed multiple myeloma – additional data from planned interim analysis of the GMMG-CONCEPT trial
35. TP53 deficiency permits chromosome abnormalities and karyotype heterogeneity in acute myeloid leukemia
36. Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma
37. Autophagic cell death restricts chromosomal instability during replicative crisis
38. A signalling rheostat controls chromosome segregation fidelity during early lineage specification and neurogenesis by modulating DNA replication stress
39. Chromosome engineering and CRISPR-Cas9 viability screening reveals increased metastatic capacity targetable by patient-specific synthetic lethality
40. AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis
41. Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia
42. Globally altered epigenetic landscape and delayed osteogenic differentiation in H3.3-G34W-mutant giant cell tumor of bone
43. Characterisation of the novel spontaneously immortalized and invasively growing human skin keratinocyte line HaSKpw
44. Brain structure and function: a multidisciplinary pipeline to study hominoid brain evolution.
45. Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma.
46. Cytogenetic abnormalities in monoclonal gammopathy of undetermined significance
47. Drug-perturbation-based stratification of blood cancer
48. Prediction of Bone Marrow Biopsy Results From MRI in Multiple Myeloma Patients Using Deep Learning and Radiomics
49. Clinical outcomes of the PAUL ® glaucoma implant: One‐year results
50. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.